Lamotrigine (All indications)

Extremely preterm (< 28 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12611
R47528		 Van Marter (Lamotrigine) (Controls unexposed, disease free), 2021 Prematurity - Extreme (<28 wk gestational age) at least 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 0.32 [0.01;7.90] C
excluded (control group) 		0/110   1/106 1 110
ref
S12613
R47540		 Van Marter (Lamotrigine) (Controls unexposed, sick), 2021 Prematurity - Extreme (<28 wk gestational age) at least 1st trimester prospective cohort unexposed, sick Adjustment: No 0.13 [0.00;6.93] C 0/110   0/15 0 110
ref
S8978
R30427		 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Gestational age at birth (22-26 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.60 [0.15;2.39] C 2/2,813   2,036/1,707,707 2,038 2,813
ref
Total 2 studies 0.51 [0.14;1.87] 2,038 2,923
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Van Marter (Lamotrigine) (Controls unexposed, sick), 2021Van Marter, 2021 1 0.13[0.00; 6.93]011011%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: low Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Coste, 2020 2 0.60[0.15; 2.39]2,0382,81389%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.51[0.14; 1.87]2,0382,9230.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Controls unexposed, sick; 2: Lamotrigine) (Controls unexposed NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.51[0.14; 1.87]2,0382,9230%NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.60[0.15; 2.39]2,0382,813 -NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 0.13[0.00; 6.93]-110 -NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 1 Tags Adjustment   - No  - No 0.51[0.14; 1.87]2,0382,9230%NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 All studiesAll studies 0.51[0.14; 1.87]2,0382,9230%NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12611

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.54[0.15; 1.93]2,0392,9230%NAVan Marter (Lamotrigine) (Controls unexposed, disease free), 2021 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 unexposed, sick controlsunexposed, sick controls Out of scale0.13[0.00; 6.93]-110 -NAVan Marter (Lamotrigine) (Controls unexposed, sick), 2021 10.510.01.0